Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)

• Sponsor: Organon and Co (Industry)
• Overall Status: Completed
• CT.gov ID: NCT00383552
• Collaborator: Novartis (Industry)
• Enrollment: 746
• Arms: 4
• Duration (Months): 23

Study Details

Study Description

Brief Summary

This is a randomized, multi-center, double-blind, double-dummy, placebo-controlled, parallel-group study, evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) versus MF for 26 weeks. Prior to the 26-week double-blind Treatment Period, participants will receive open-label (OL) MF MDI 100 mcg twice daily (BID) for 2 to 3 weeks during the Run-in Period. Efficacy will be measured by the Area Under the Curve from 0 to 12 hours [AUC](0-12 hours) of the change from Baseline to the Week 12 Endpoint in Forced Expiratory Volume in One Second (FEV1) and by the time-to-first severe asthma exacerbation across the 26-week treatment period.

Condition or Disease	Intervention/Treatment	Phase
Asthma	Drug: Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID; Drug: Mometasone Furoate MDI (MF MDI); Drug: Formoterol Fumarate 10 mcg; Drug: Placebo	Phase 3

Study Design

• Study Type: Interventional
• Actual Enrollment: 746 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids
• Study Start Date: Sep 1, 2006
• Actual Primary Completion Date: Aug 1, 2008
• Actual Study Completion Date: Aug 1, 2008

Arms and Interventions

Arm	Intervention/Treatment
Experimental: MF/F MDI 100/10 mcg BID	Drug: Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID; MF/F 100/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks; Other Names: SCH 418131
Experimental: MF MDI 100 mcg BID	Drug: Mometasone Furoate MDI (MF MDI); MF 100 mcg via metered dose inhaler twice daily for 26 weeks; Other Names: SCH 32088
Experimental: F MDI 10 mcg BID	Drug: Formoterol Fumarate 10 mcg; F via metered dose inhaler 10 mcg twice a day for 26 weeks; Other Names: Foradil
Placebo Comparator: Placebo BID	Drug: Placebo; Placebo metered dose inhaler twice a day for 26 weeks

Outcome Measures

Primary Outcome Measures

1. Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) [Baseline to Week 12]

   The average of the two predose FEV1 measurements (30 minutes prior to dosing and 0 hour, immediately prior to dosing) at the Baseline Visit were subtracted from each of the serial measurements over the 12-hour period. The AUC was calculated based on these changes from Baseline evaluations. The comparison was for MF/F vs MF. Standard deviation was pooled.

2. Median Time-to-first Severe Asthma Exacerbation Over the 26-week Treatment Period [Across the 26 week treatment period]

   Severe asthma exacerbation refers to an occurrence of a decrease below 80% of Baseline in FEV1, a decrease below 70% of Baseline in PEF on 2 consecutive days or a clinical deterioration of asthma resulting in emergency treatment, hospitalization or treatment with asthma medication.

3. Number of Participants With at Least One Severe Asthma Exacerbation at Week 26 [Week 26]

   Severe asthma exacerbation refers to an occurrence of a decrease below 80% of Baseline in FEV1, a decrease below 70% of Baseline in PEF on 2 consecutive days and or a clinical deterioration of asthma resulting in emergency treatment, hospitalization or treatment with asthma medication.

Secondary Outcome Measures

1. Change From Baseline to Week 26 in the Asthma Control Questionnaire (ACQ) Total Score [Baseline to Week 26]

   ACQ consists of seven questions each scaled from 0 (best case) to 6 (worst case). The comparison was for MF/F vs placebo. Standard deviation was pooled.

2. Change From Baseline to Week 26 in Asthma Quality of Life Questionnaire With Standarized Activities (AQLQ[S]) Total Score [Baseline to Week 26]

   AQLQ(S) consists of 32 questions each scaled from 1 (worst case) to 7 (best case). The comparison was for MF/F vs placebo. Standard deviation was pooled.

3. Change From Baseline in Proportion of Nights Across the Treatment Period With Nocturnal Awakenings Due to Asthma Which Require Use of Short-acting Beta Agonists (SABA) [Baseline to Endpoint]

   Baseline is the proportion of nights of the last week (Days -7 to 1) prior to first dose with nocturnal awakenings. Scale is measured as 0 to 1 with 0=no awakenings to 1=awakenings every night. The comparison was for MF/F vs placebo. Standard deviation was pooled.

4. Change From Baseline in AM FEV1 Pre-dose Assessment, or Trough FEV1, at Week 12 [Baseline to Week 12]

   Trough FEV1 is a measure of the end-of-dosing interval. The comparison was for MF/F vs F. Standard deviation was pooled.

5. AUC(0-12 Hour) of the Change From Baseline to Week 12 in FEV1 for Each Body Mass Index (BMI) Subgroup [Baseline to Week 12]

   The average of the two predose FEV1 measurements (30 minutes prior to dosing and 0 hour, immediately prior to dosing) at the Baseline Visit were subtracted from each of the serial measurements over the 12-hour period. The AUC was calculated based on these changes from Baseline evaluations. BMI is a number calculated from a person's weight and height. The higher the number, the higher the amount of fat. The comparison was for MF/F vs placebo. Standard deviation was pooled.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 12 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• =12 years, either sex, any race, asthma diagnosis >=12 months that is consistent with the following: Diagnosis based on clinical history & examination, pulmonary function parameters & response to beta-2-agonists, according to international guidelines.

• Been using low daily dose of inhaled corticosteroid (ICS) (either alone or in combination with long-acting beta agonist [LABA]) >=12 weeks & been on stable asthma regimen for >=2 weeks prior to Screening. Low daily doses of ICS are:

200-500 mcg beclomethasone chlorofluorocarbon (CFC),

100-250 mcg beclomethasone hydrofluoroalkane (HFA),

200-600 mcg budesonide dry powder inhaler (DPI),

500-1000 mcg flunisolide,

100-250 mcg fluticasone,

200 mcg MF,

400-1000 mcg triamcinolone acetonide,

80 to 160 mcg ciclesonide.

Note: Dose delivery by method/modality other than these must be equivalent.

• No harm in changing current asthma therapy to investigator, subject (legal representation, if applicable) must be willing to discontinue his/her ICS or ICS/LABA combination prior to initiating MF MDI run-in medication at Screening Visit, & transferred to open-label treatment with MF MDI 100 mcg BID for 2-3 weeks prior to Baseline Visit.

• To document diagnosis of asthma & assure responsiveness to bronchodilators before randomization 1 of these can be used at Screening Visit or thereafter, but prior to

Baseline Visit:

Demonstrate increase in absolute FEV1 >=12% & >=200 mL within approximately 15 to 20 minutes after administration of 4 inhalations of albuterol/salbutamol (total dose 360-400 mcg) or nebulized short-acting beta agonist (SABA) (2.5 mg) if confirmed as standard office practice, OR

Demonstrate peak expiratory flow (PEF) variability >20% expressed as percentage of the mean highest & lowest morning prebronchodilator (before taking albuterol/salbutamol) PEF over

=1 week, OR

Demonstrate diurnal variation in PEF of >20% based on difference between prebronchodilator (before taking albuterol/salbutamol) morning value & postbronchodilator value (after taking albuterol/salbutamol) from evening before, expressed as percentage of mean daily PEF value.

• At Screening Visit, FEV1 must be >=60% & <=90% predicted.

• At Baseline Visit, FEV1 must be >=60% & <=85% predicted when all restricted drugs have been withheld for appropriate intervals.

• Lab tests at Screening Visit must be normal or acceptable to investigator/sponsor and include serum pregnancy for females of child-bearing potential). Electrocardiogram (ECG) at Screening Visit, using centralized trans-telephonic technology must be acceptable to investigator. Chest x-ray performed at Screening Visit or within 12 months prior to Screening Visit must be acceptable to investigator.

• Subject (legal representation, if applicable) must be willing to give written informed consent & able to adhere to schedules.

• A non-pregnant woman of childbearing potential must use birth control. Includes: hormonal contraceptives including hormonal vaginal ring, hormonal implant or depot-injectable; Intrauterine device (IUD); medically prescribed topically-applied transdermal contraceptive patch; condom in combination with spermicide; monogamous relationship with male who had vasectomy. Started birth control method >=3 months prior to Screening (exception condom), & must agree to continue its use. Female of childbearing potential who is not currently sexually active must agree & consent to using birth control, should she become active. Women who have been surgically sterilized or are >=1 year postmenopausal are not considered to be of childbearing potential. Female must have negative serum pregnancy test at Screening.

Exclusion Criteria:

• Increase/decrease in absolute FEV1 of >20% at any time from Screening Visit up to & including Baseline Visit. Pulmonary function tests (PFTs) will be performed in the morning.

• 8 inhalations/day of SABA MDI or >=2 nebulized treatments/day of 2.5 mg SABA on 2 consecutive days from Screening Visit up to & including Baseline Visit.

• Decrease in AM/PM PEF below Screening Period stability limit on 2 consecutive days prior to randomization.

• Asthma deterioration results in emergency treatment, hospitalization, or treatment with additional, excluded asthma medication (including oral or other systemic corticosteroids, but allowing SABA) as judged by investigator at any time from Screening Visit up to & including Baseline Visit.

• Treated in emergency room (ER) (for severe asthma exacerbation requiring systemic glucocorticosteroid treatment) or admitted to hospital for management of airway obstruction within last 3 months.

• Ever required ventilator support for respiratory failure secondary to asthma.

• Upper/lower respiratory tract infection within previous 2 weeks prior to Screening & Baseline Visits. Visits can be rescheduled 2 weeks after complete resolution.

• Smoker or ex-smoker & has smoked within previous year or has cumulative smoking history >10 pack-years.

• Significant abnormal vital sign.

• Evidence upon visual inspection of significant oropharyngeal candidiasis at Baseline or earlier with or without treatment. If there is evidence at Screening or Pre-Baseline Visit, may be treated as appropriate & Baseline Visit can be scheduled upon resolution.

• History of significant renal, hepatic, cardiovascular, metabolic, neurologic, hematologic, ophthalmologic, respiratory, gastrointestinal, cerebrovascular, or other which, in judgment of investigator, could interfere with study or require treatment which might interfere with study. Examples include (but are not limited to) insulin-dependent diabetes, hypertension being treated with beta-blockers, active hepatitis, coronary artery disease, arrhythmia, significant QTc prolongation (ie QTcF or QTcB [Fridericia or Bazett corrections, respectively >500 msecs), stroke, severe rheumatoid arthritis, chronic open-angle glaucoma or posterior subcapsular cataracts (including prior cataract surgery), acquired immune deficiency syndrome (AIDS), or conditions that may interfere with respiratory function such as chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis. Others which are well-controlled & stable (eg hypertension not requiring beta-blockers) will not prohibit participation if deemed appropriate by investigator.

• Allergic/intolerant of glucocorticoids, beta-2-agonists, or any inactive excipients in study drugs.

• Female who is breast-feeding, pregnant, or intends to become pregnant while in study.

• Illicit drug user.

• Human immunodeficiency virus (HIV) positive (testing not done).

• Unable to use oral MDI inhaler.

• Has been taking any restricted medications prior to Screening without meeting required washout.

• Cannot adhere to prohibited & permitted concomitant medications.

• May not participate in same study at another site. Cannot participate in different study at any site, during same time.

• Must not be randomized into study more than once.

• No person directly associated with administration of study may participate.

• Previously participated in trial with MF/F.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Organon and Co
• Novartis

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Organon and Co
• ClinicalTrials.gov Identifier: NCT00383552
• Other Study ID Numbers: P04073; Doc ID: 3100873;; EUDRACT No: 2006-001577-13
• First Posted: Oct 3, 2006
• Last Update Posted: Feb 15, 2022
• Last Verified: Feb 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Additional relevant MeSH terms: Asthma; Mometasone Furoate; Formoterol Fumarate

Study Results

Participant Flow

Arm/Group Title	MF/F MDI 100/10 mcg BID	MF MDI 100 mcg BID	F MDI 10 mcg BID	Placebo BID
Arm/Group Description	Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)	Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)	Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)	Placebo twice daily (BID)
Period Title: Overall Study
STARTED	182	188	188	188
COMPLETED	146	147	127	116
NOT COMPLETED	36	41	61	72

Baseline Characteristics

Arm/Group Title	MF/F MDI 100/10 mcg BID	MF MDI 100 mcg BID	F MDI 10 mcg BID	Placebo BID	Total
Arm/Group Description	Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)	Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)	Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)	Placebo twice daily (BID)	Total of all reporting groups
Overall Participants	182	188	188	188	746
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	37.1 (16.9)	39.4 (16.7)	38.5 (15.6)	38.1 (17.4)	38.3 (16.6)
Sex: Female, Male (Count of Participants)
Female	99 54.4%	105 55.9%	103 54.8%	106 56.4%	413 55.4%
Male	83 45.6%	83 44.1%	85 45.2%	82 43.6%	333 44.6%

Outcome Measures

1. Primary Outcome

Title	Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)
Description	The average of the two predose FEV1 measurements (30 minutes prior to dosing and 0 hour, immediately prior to dosing) at the Baseline Visit were subtracted from each of the serial measurements over the 12-hour period. The AUC was calculated based on these changes from Baseline evaluations. The comparison was for MF/F vs MF. Standard deviation was pooled.
Time Frame	Baseline to Week 12

Outcome Measure Data

Analysis Population Description

Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).

Arm/Group Title	MF/F MDI 100/10 mcg BID	MF MDI 100 mcg BID	F MDI 10 mcg BID	Placebo BID
Arm/Group Description	Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)	Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)	Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)	Placebo twice daily (BID)
Measure Participants	155	156	146	129
Baseline	3.94 (3.29)	1.85 (3.29)	4.09 (3.29)	1.64 (3.29)
Change from Baseline	4.00 (3.71)	2.53 (3.71)	3.83 (3.71)	1.11 (3.71)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	MF/F MDI 100/10 mcg BID, MF MDI 100 mcg BID
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.001
	Comments
	Method	ANCOVA
	Comments

2. Secondary Outcome

Title	Change From Baseline to Week 26 in the Asthma Control Questionnaire (ACQ) Total Score
Description	ACQ consists of seven questions each scaled from 0 (best case) to 6 (worst case). The comparison was for MF/F vs placebo. Standard deviation was pooled.
Time Frame	Baseline to Week 26

Outcome Measure Data

Analysis Population Description

Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).

Arm/Group Title	MF/F MDI 100/10 mcg BID	MF MDI 100 mcg BID	F MDI 10 mcg BID	Placebo BID
Arm/Group Description	Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)	Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)	Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)	Placebo twice daily (BID)
Measure Participants	143	145	129	116
Baseline	1.34 (0.71)	1.29 (0.60)	1.38 (0.76)	1.23 (0.71)
Change from Baseline	-0.40 (0.65)	-0.32 (0.65)	-0.12 (0.65)	-0.11 (0.65)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	MF/F MDI 100/10 mcg BID, Placebo BID
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.001
	Comments
	Method	ANCOVA
	Comments

3. Primary Outcome

Title	Median Time-to-first Severe Asthma Exacerbation Over the 26-week Treatment Period
Description	Severe asthma exacerbation refers to an occurrence of a decrease below 80% of Baseline in FEV1, a decrease below 70% of Baseline in PEF on 2 consecutive days or a clinical deterioration of asthma resulting in emergency treatment, hospitalization or treatment with asthma medication.
Time Frame	Across the 26 week treatment period

Outcome Measure Data

Analysis Population Description

Medians for time-to-event outcomes are estimated for those who had events.

Arm/Group Title	MF/F MDI 100/10 Mcg BID	MF MDI 100 Mcg BID	F MDI 10 Mcg BID	Placebo BID
Arm/Group Description	Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID).	Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID).	Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID).	Placebo twice daily (BID).
Measure Participants	30	53	84	86
Median (Inter-Quartile Range) [Days]	45.5 (101)	54 (98)	51.5 (125.5)	27.5 (87)

4. Secondary Outcome

Title	Change From Baseline to Week 26 in Asthma Quality of Life Questionnaire With Standarized Activities (AQLQ[S]) Total Score
Description	AQLQ(S) consists of 32 questions each scaled from 1 (worst case) to 7 (best case). The comparison was for MF/F vs placebo. Standard deviation was pooled.
Time Frame	Baseline to Week 26

Outcome Measure Data

Analysis Population Description

Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).

Arm/Group Title	MF/F MDI 100/10 mcg BID	MF MDI 100 mcg BID	F MDI 10 mcg BID	Placebo BID
Arm/Group Description	Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)	Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)	Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)	Placebo twice daily (BID)
Measure Participants	144	147	129	117
Baseline	5.60 (0.93)	5.65 (1.00)	5.60 (0.98)	5.76 (1.02)
Change from Baseline	0.44 (0.73)	0.39 (0.73)	0.15 (0.73)	0.06 (0.73)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	MF/F MDI 100/10 mcg BID, Placebo BID
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	ANCOVA
	Comments

5. Secondary Outcome

Title	Change From Baseline in Proportion of Nights Across the Treatment Period With Nocturnal Awakenings Due to Asthma Which Require Use of Short-acting Beta Agonists (SABA)
Description	Baseline is the proportion of nights of the last week (Days -7 to 1) prior to first dose with nocturnal awakenings. Scale is measured as 0 to 1 with 0=no awakenings to 1=awakenings every night. The comparison was for MF/F vs placebo. Standard deviation was pooled.
Time Frame	Baseline to Endpoint

Outcome Measure Data

Analysis Population Description

Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).

Arm/Group Title	MF/F MDI 100/10 mcg BID	MF MDI 100 mcg BID	F MDI 10 mcg BID	Placebo BID
Arm/Group Description	Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)	Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)	Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)	Placebo twice daily (BID)
Measure Participants	181	185	185	188
Baseline	0.13 (0.12)	0.12 (0.12)	0.15 (0.15)	0.13 (0.14)
Change from Baseline	-0.06 (0.16)	-0.03 (0.16)	-0.03 (0.16)	0.02 (0.16)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	MF/F MDI 100/10 mcg BID, Placebo BID
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	ANCOVA
	Comments

6. Secondary Outcome

Title	Change From Baseline in AM FEV1 Pre-dose Assessment, or Trough FEV1, at Week 12
Description	Trough FEV1 is a measure of the end-of-dosing interval. The comparison was for MF/F vs F. Standard deviation was pooled.
Time Frame	Baseline to Week 12

Outcome Measure Data

Analysis Population Description

Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).

Arm/Group Title	MF/F MDI 100/10 mcg BID	MF MDI 100 mcg BID	F MDI 10 mcg BID	Placebo BID
Arm/Group Description	Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)	Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)	Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)	Placebo twice daily (BID)
Measure Participants	160	163	160	137
Baseline	2.50 (2.56)	2.41 (2.46)	2.47 (2.52)	2.46 (2.50)
Change from Baseline	0.18 (0.21)	0.16 (0.21)	0.11 (0.21)	0.04 (0.21)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	MF/F MDI 100/10 mcg BID, F MDI 10 mcg BID
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.073
	Comments
	Method	Longitudinal Model
	Comments

7. Secondary Outcome

Title	AUC(0-12 Hour) of the Change From Baseline to Week 12 in FEV1 for Each Body Mass Index (BMI) Subgroup
Description	The average of the two predose FEV1 measurements (30 minutes prior to dosing and 0 hour, immediately prior to dosing) at the Baseline Visit were subtracted from each of the serial measurements over the 12-hour period. The AUC was calculated based on these changes from Baseline evaluations. BMI is a number calculated from a person's weight and height. The higher the number, the higher the amount of fat. The comparison was for MF/F vs placebo. Standard deviation was pooled.
Time Frame	Baseline to Week 12

Outcome Measure Data

Analysis Population Description

Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).

Arm/Group Title	MF/F MDI 100/10 mcg BID	MF MDI 100 mcg BID	F MDI 10 mcg BID	Placebo BID
Arm/Group Description	Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)	Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)	Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)	Placebo twice daily (BID)
Measure Participants	155	156	146	128
Less than 25	5.24 (4.42)	3.19 (4.42)	4.34 (4.42)	2.22 (4.42)
25 to less than 30	3.36 (4.14)	3.23 (4.14)	4.26 (4.14)	1.22 (4.14)
30 or more	3.35 (3.68)	1.69 (3.68)	3.13 (3.68)	-0.73 (3.68)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	MF/F MDI 100/10 mcg BID, Placebo BID
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.015
	Comments	BMI 25 to <30
	Method	ANCOVA
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	MF/F MDI 100/10 mcg BID, Placebo BID
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	BMI less than 25 and for BMI 30 or more
	Method	ANCOVA
	Comments

8. Primary Outcome

Title	Number of Participants With at Least One Severe Asthma Exacerbation at Week 26
Description	Severe asthma exacerbation refers to an occurrence of a decrease below 80% of Baseline in FEV1, a decrease below 70% of Baseline in PEF on 2 consecutive days and or a clinical deterioration of asthma resulting in emergency treatment, hospitalization or treatment with asthma medication.
Time Frame	Week 26

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	MF/F MDI 100/10 mcg BID	MF MDI 100 mcg BID	F MDI 10 mcg BID	Placebo BID
Arm/Group Description	Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)	Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)	Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)	Placebo twice daily (BID)
Measure Participants	155	156	146	129
Number [participants]	30 16.5%	53 28.2%	84 44.7%	86 45.7%

Adverse Events

Adverse Event Reporting Description	All participants treated with OL MF MDI and/or double-blind study medication are included in the safety population.
Arm/Group Title	OL MF MDI 100 MCG BID		MF/F MDI 100/10 MCG BID		MF MDI 100 MCG BID		F MDI 10 MCG BID		PLACEBO
Arm/Group Description	Open-label (OL) mometasone furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID). Participants received 2- to 3-weeks (approximately) of open-label run-in with MF MDI 100 mcg BID prior to the 26-week double-blind Treatment Period.
All Cause Mortality
	OL MF MDI 100 MCG BID		MF/F MDI 100/10 MCG BID		MF MDI 100 MCG BID		F MDI 10 MCG BID		PLACEBO
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)
Serious Adverse Events
	OL MF MDI 100 MCG BID		MF/F MDI 100/10 MCG BID		MF MDI 100 MCG BID		F MDI 10 MCG BID		PLACEBO
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	2/882 (0.2%)		4/182 (2.2%)		5/188 (2.7%)		1/188 (0.5%)		1/188 (0.5%)
Cardiac disorders
PULMONARY VALVE STENOSIS	0/882 (0%)	0	1/182 (0.5%)	1	0/188 (0%)	0	0/188 (0%)	0	0/188 (0%)	0
Ear and labyrinth disorders
DEAFNESS	0/882 (0%)	0	0/182 (0%)	0	1/188 (0.5%)	1	0/188 (0%)	0	0/188 (0%)	0
Endocrine disorders
GOITRE	0/882 (0%)	0	1/182 (0.5%)	1	0/188 (0%)	0	0/188 (0%)	0	0/188 (0%)	0
Gastrointestinal disorders
DUODENAL ULCER	0/882 (0%)	0	0/182 (0%)	0	1/188 (0.5%)	1	0/188 (0%)	0	0/188 (0%)	0
General disorders
ASTHENIA	0/882 (0%)	0	0/182 (0%)	0	1/188 (0.5%)	1	0/188 (0%)	0	0/188 (0%)	0
Infections and infestations
APPENDICITIS	0/882 (0%)	0	0/182 (0%)	0	1/188 (0.5%)	1	0/188 (0%)	0	0/188 (0%)	0
VIRAL PERICARDITIS	0/882 (0%)	0	0/182 (0%)	0	1/188 (0.5%)	1	0/188 (0%)	0	0/188 (0%)	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
UTERINE LEIOMYOMA	0/882 (0%)	0	1/182 (0.5%)	1	0/188 (0%)	0	0/188 (0%)	0	0/188 (0%)	0
Reproductive system and breast disorders
DYSFUNCTIONAL UTERINE BLEEDING	0/882 (0%)	0	1/182 (0.5%)	1	0/188 (0%)	0	0/188 (0%)	0	0/188 (0%)	0
FALLOPIAN TUBE CYST	1/882 (0.1%)	1	0/182 (0%)	0	0/188 (0%)	0	0/188 (0%)	0	0/188 (0%)	0
Respiratory, thoracic and mediastinal disorders
ASTHMA	1/882 (0.1%)	1	0/182 (0%)	0	0/188 (0%)	0	0/188 (0%)	0	0/188 (0%)	0
PNEUMOTHORAX	0/882 (0%)	0	1/182 (0.5%)	1	0/188 (0%)	0	0/188 (0%)	0	0/188 (0%)	0
PULMONARY EMBOLISM	0/882 (0%)	0	0/182 (0%)	0	0/188 (0%)	0	0/188 (0%)	0	1/188 (0.5%)	1
Skin and subcutaneous tissue disorders
HYPERHIDROSIS	0/882 (0%)	0	0/182 (0%)	0	1/188 (0.5%)	1	0/188 (0%)	0	0/188 (0%)	0
Vascular disorders
HYPERTENSION	0/882 (0%)	0	0/182 (0%)	0	0/188 (0%)	0	1/188 (0.5%)	1	0/188 (0%)	0
Other (Not Including Serious) Adverse Events
	OL MF MDI 100 MCG BID		MF/F MDI 100/10 MCG BID		MF MDI 100 MCG BID		F MDI 10 MCG BID		PLACEBO
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	22/882 (2.5%)		33/182 (18.1%)		37/188 (19.7%)		32/188 (17%)		24/188 (12.8%)
Infections and infestations
NASOPHARYNGITIS	3/882 (0.3%)	3	17/182 (9.3%)	19	13/188 (6.9%)	15	7/188 (3.7%)	7	5/188 (2.7%)	5
UPPER RESPIRATORY TRACT INFECTION	5/882 (0.6%)	5	10/182 (5.5%)	11	17/188 (9%)	19	20/188 (10.6%)	26	12/188 (6.4%)	17
Nervous system disorders
HEADACHE	15/882 (1.7%)	18	12/182 (6.6%)	17	11/188 (5.9%)	18	9/188 (4.8%)	9	7/188 (3.7%)	10

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The investigator agrees not to publish/present any interim results without prior sponsor written consent. The investigator agrees to provide to the sponsor, 45 days prior to submission, review copies for publication that report any study results. The sponsor has the right to review and comment. If the parties disagree, investigator agrees to meet with the sponsor, prior to submission for publication, to discuss and resolve any such issues/disagreement.